162 related articles for article (PubMed ID: 20433322)
1. Predicting response to lithium in bipolar disorder: a critical review of pharmacogenetic studies.
Smith DJ; Evans R; Craddock N
J Ment Health; 2010 Apr; 19(2):142-56. PubMed ID: 20433322
[TBL] [Abstract][Full Text] [Related]
2. [Predictors of prophylactic response to lithium].
Rohayem J; Baylé JF; Richa S
Encephale; 2008 Sep; 34(4):394-9. PubMed ID: 18922242
[TBL] [Abstract][Full Text] [Related]
3. Twenty years of Lithium pharmacogenetics: A systematic review.
Pagani R; Gasparini A; Ielmini M; Caselli I; Poloni N; Ferrari M; Marino F; Callegari C
Psychiatry Res; 2019 Aug; 278():42-50. PubMed ID: 31146140
[TBL] [Abstract][Full Text] [Related]
4. A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients.
Moore GJ; Cortese BM; Glitz DA; Zajac-Benitez C; Quiroz JA; Uhde TW; Drevets WC; Manji HK
J Clin Psychiatry; 2009 Apr; 70(5):699-705. PubMed ID: 19389332
[TBL] [Abstract][Full Text] [Related]
5. Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified.
Greil W; Kleindienst N
Int Clin Psychopharmacol; 1999 Sep; 14(5):283-5. PubMed ID: 10529071
[TBL] [Abstract][Full Text] [Related]
6. Possible relationship between mitochondrial DNA polymorphisms and lithium response in bipolar disorder.
Washizuka S; Ikeda A; Kato N; Kato T
Int J Neuropsychopharmacol; 2003 Dec; 6(4):421-4. PubMed ID: 14604458
[TBL] [Abstract][Full Text] [Related]
7. Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge.
Rybakowski JK
CNS Drugs; 2013 Mar; 27(3):165-73. PubMed ID: 23378337
[TBL] [Abstract][Full Text] [Related]
8. The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder.
Greil W; Kleindienst N
Int Clin Psychopharmacol; 1999 Sep; 14(5):277-81. PubMed ID: 10529070
[TBL] [Abstract][Full Text] [Related]
9. Clinical and pathogenic aspects of candidate genes for lithium prophylactic efficacy.
Rybakowski JK; Czerski P; Dmitrzak-Weglarz M; Kliwicki S; Leszczynska-Rodziewicz A; Permoda-Osip A; Skibinska M; Suwalska A; Szczepankiewicz A; Hauser J
J Psychopharmacol; 2012 Mar; 26(3):368-73. PubMed ID: 21890592
[TBL] [Abstract][Full Text] [Related]
10. Biological predictors of lithium response in bipolar disorder.
Ikeda A; Kato T
Psychiatry Clin Neurosci; 2003 Jun; 57(3):243-50. PubMed ID: 12753562
[TBL] [Abstract][Full Text] [Related]
11. Association study of the INPP1, 5HTT, BDNF, AP-2beta and GSK-3beta GENE variants and restrospectively scored response to lithium prophylaxis in bipolar disorder.
Michelon L; Meira-Lima I; Cordeiro Q; Miguita K; Breen G; Collier D; Vallada H
Neurosci Lett; 2006 Aug; 403(3):288-93. PubMed ID: 16787706
[TBL] [Abstract][Full Text] [Related]
12. Association studies of 5-HT2A and 5-HT2C serotonin receptor gene polymorphisms with prophylactic lithium response in bipolar patients.
Dmitrzak-Weglarz M; Rybakowski JK; Suwalska A; Słopień A; Czerski PM; Leszczyńska-Rodziewicz A; Hauser J
Pharmacol Rep; 2005; 57(6):761-5. PubMed ID: 16382194
[TBL] [Abstract][Full Text] [Related]
13. Prophylaxis of schizoaffective disorder with lithium or carbamazepine: outcome after long-term follow-up.
Baethge C; Gruschka P; Berghöfer A; Bauer M; Müller-Oerlinghausen B; Bschor T; Smolka MN
J Affect Disord; 2004 Apr; 79(1-3):43-50. PubMed ID: 15023479
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of lithium response in bipolar disorder.
Alda M
J Psychiatry Neurosci; 1999 Mar; 24(2):154-8. PubMed ID: 10212559
[TBL] [Abstract][Full Text] [Related]
15. [Long-term treatment of bipolar disorder: how should we use lithium salts?].
Del Grande C; Muti M; Musetti L; Pergentini I; Corsi M; Turri M; Soldani I; Corsini GU; Dell'Osso L
Riv Psichiatr; 2012; 47(6):515-26. PubMed ID: 23160112
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetic aspects of bipolar disorder.
Alda M
Pharmacogenomics; 2003 Jan; 4(1):35-40. PubMed ID: 12517284
[TBL] [Abstract][Full Text] [Related]
17. [Methodological approach to inter "guideline" variability in the management of bipolar disorders].
Samalin L; Llorca PM
Encephale; 2012 Apr; 38(2):126-32. PubMed ID: 22516270
[TBL] [Abstract][Full Text] [Related]
18. Inositol monophosphatase, the putative therapeutic target for lithium.
Atack JR
Brain Res Brain Res Rev; 1996 Aug; 22(2):183-90. PubMed ID: 8883919
[TBL] [Abstract][Full Text] [Related]
19. Long-term stability of cognitive impairment in bipolar disorder: a 2-year follow-up study of lithium-treated euthymic bipolar patients.
Mur M; Portella MJ; Martínez-Arán A; Pifarré J; Vieta E
J Clin Psychiatry; 2008 May; 69(5):712-9. PubMed ID: 18435565
[TBL] [Abstract][Full Text] [Related]
20. The new lithium clinic.
Osher Y; Bersudsky Y; Belmaker RH
Neuropsychobiology; 2010; 62(1):17-26. PubMed ID: 20453531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
